FA

Fusion Antibodies PLCLSE Fusion Antibodies Stock Report

Last reporting period 31 Mar, 2024

Updated 29 Oct, 2024

Last price

Market cap $B

0.005

Micro

Exchange

XLON - London Stock Exchange

FAB.L Stock Analysis

FA

Uncovered

Fusion Antibodies PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-51/100

Low score

Market cap $B

0.005

Dividend yield

Shares outstanding

26.015 B

Fusion Antibodies Plc engages in research, development, and manufacturing recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The company is headquartered in Belfast, Northern Ireland and currently employs 53 full-time employees. The company went IPO on 2017-12-18. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. Its services include discovery, engineering, and supply. Discovery services include creation, screening and sequencing of novel monoclonal antibodies for therapeutic and diagnostic applications. Engineering services maximizing the performance of an antibody drug, including CDRx humanization, Antibody Developability by Design (ADDTM), RAMPTM, and OptiMASTM. Supply services include production of material for clinical production or further research, including transient expression and cGMP ready stable cell line development.

View Section: Eyestock Rating